Effective Systolic Blood Pressure Reduction with Olmesartan Medoxomil/Amlodipine Combination TherapyPost Hoc Analysis of Data from a Randomized, Double-Blind, Parallel-Group, Multicentre Study

被引：0
|
作者：
Jean-Jacques Mourad
Sylvain Le Jeune
机构：
[1] Avicenne Hospital—Hypertension Unit and University Paris XIII,Assistance Publique
来源：
Clinical Drug Investigation | 2009年 / 29卷
关键词：
Systolic Blood Pressure; Amlodipine; HCTZ; Olmesartan; Olmesartan Medoxomil;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and objective: Systolic blood pressure (SBP) strongly predicts cardiovascular risk and is an important factor to evaluate in studies of anti-hypertensive treatments. A recent randomized controlled study has shown that the angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) olmesartan medoxomil (hereafter olmesartan) combined with the calcium channel antagonist (calcium channel blocker) amlodipine can control SBP in a majority of patients with moderate-to-severe hypertension. The aim of this report is to present results from a post hoc analysis of this study to further evaluate the effects of this combination on SBP.
引用
收藏
页码：419 / 425
页数：6
相关论文
共 50 条
  • [41] Tolerability and safety profiles of metformin-glibenclamide combination tablets: new analyses from multicentre, parallel-group, double-blind, randomised, clinical trials
    Howlett, HCS
    Cugnardey, N
    Bruce, S
    Cornes, M
    DIABETOLOGIA, 2004, 47 : A251 - A251
  • [42] Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence
    Boedeker, Rolf-Hasso
    Madersbacher, Helmut
    Neumeister, Claudia
    Zellner, Michael
    BMC UROLOGY, 2010, 10
  • [43] Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study
    Björn Ställberg
    Olof Selroos
    Claus Vogelmeier
    Eva Andersson
    Tommy Ekström
    Kjell Larsson
    Respiratory Research, 10
  • [44] Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study
    Stallberg, Bjorn
    Selroos, Olof
    Vogelmeier, Claus
    Andersson, Eva
    Ekstrom, Tommy
    Larsson, Kjell
    RESPIRATORY RESEARCH, 2009, 10
  • [45] Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence
    Rolf-Hasso Bödeker
    Helmut Madersbacher
    Claudia Neumeister
    Michael Zellner
    BMC Urology, 10
  • [46] Efficacy and safety of Yi Shen Fang granules in elderly people with MCI: study protocol for a multicentre, randomized, double-blind, parallel-group, controlled trial
    Zhongwei Sha
    Zhenghao Zhao
    Nana Li
    Shuyun Xiao
    Ou Li
    Jie Zhang
    Zhimin Li
    Jian Xu
    BMC Complementary Medicine and Therapies, 23
  • [47] The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study
    Ghali, Jalal K.
    Orlandi, Cesare
    Abraham, William T.
    EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (06) : 642 - 651
  • [48] A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis
    Dahlberg, L. E.
    Holme, I.
    Hoye, K.
    Ringertz, B.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2009, 38 (02) : 133 - 143
  • [49] Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: A multicentre, double-blind, randomized, parallel-group Phase II study
    Suzuki, Yasuo
    Motoya, Satoshi
    Takazoe, Masakazu
    Kosaka, Tadashi
    Date, Masataka
    Nii, Masahiro
    Hibi, Toshifumi
    JOURNAL OF CROHNS & COLITIS, 2013, 7 (03): : 239 - 247
  • [50] Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study
    Kaku, K.
    Katou, M.
    Igeta, M.
    Ohira, T.
    Sano, H.
    DIABETES OBESITY & METABOLISM, 2015, 17 (12): : 1198 - 1201
12345